India Pharma Serialization 2026: Schedule H2 QR Rules & CDSCO Compliance
- Share
- publisher
- QS DEFENDER Compliance Team
- Issue Time
- Nov 7,2026
Summary
India's 2026 amendment expands Schedule H2 QR-based drug traceability to vaccines, antimicrobials, and anti-cancer medicines. This guide explains CDSCO's requirements, the nine mandated data elements, phased 2027/2028 deadlines, and how batch-level QR authentication helps Indian pharma brands fight counterfeits.
India has expanded its QR-code drug traceability rules in 2026. If your company makes or exports vaccines, antimicrobials, anti-cancer medicines, or narcotic and psychotropic drugs, the Schedule H2 framework now applies to you. This guide breaks down what changed, the nine data elements CDSCO expects on every pack, the phased 2027 and 2028 deadlines, and how batch-level QR authentication helps Indian brands protect patients and meet export rules at the same time.
Why Indian Pharma Brands Are Watching Schedule H2 in 2026
In June 2026, the Union Ministry of Health and Family Welfare notified amendments to the Drugs Rules, 1945 (G.S.R. 506(E)) that widen the Schedule H2 QR-code track-and-trace framework well beyond the original "top 300 brands" mandate of 2023. The change brings entire drug categories under a single, scannable authentication standard and gives regulators a digital spine for spotting spurious and substandard medicines. For manufacturers, the practical question is no longer whether to print a QR code, but what to encode and how to keep that data trustworthy across the supply chain.
What the 2026 Amendment Actually Changes
Schedule H2 of the Drugs Rules, 1945 already required the top 300 pharmaceutical brands to carry a barcode or QR code on their labels. The 2026 amendment extends that obligation to all vaccines, antimicrobials, narcotic and psychotropic drugs (under the NDPS Act, 1985), and all anti-cancer medicines. CDSCO issues implementation guidance, while day-to-day enforcement sits with State Licensing Authorities under the existing Drugs Rules framework. Crucially, the amendment created no new penalty clause; it inherits the same risk-based inspection, stop-production, and licence-cancellation powers already in force.
At a glance
- G.S.R. 506(E) notified by the Ministry of Health and Family Welfare, 25 June 2026 (PIB Press Release PRID 2277691).
- Newly covered: vaccines, antimicrobials, anti-cancer, and narcotic/psychotropic drugs.
- Print or affix a barcode or QR code on primary packaging, or secondary packaging where space is inadequate.
- Voluntary early adoption is encouraged ahead of the notified dates.
The Nine Data Elements Every Schedule H2 Pack Must Carry
A compliant Schedule H2 code is not just a link; it must carry nine key data elements so that a product can be authenticated and verified at every stage of the supply chain. The code must be readable through software applications, which means the data should resolve to a page or system that displays the following:
1. Unique product ID
A product identification code that distinguishes the formulation.
2. Proper & generic name
The proper and generic name of the drug.
3. Brand name
The brand under which the product is marketed.
4. Manufacturer
Name and address of the manufacturer.
5. Batch number
The production batch identifier.
6. Date of manufacture
When the batch was produced.
7. Date of expiry
The product's expiry date.
8. Licence number
The manufacturing licence number.
9. Excipients
Details of excipients wherever applicable.
Phased Deadlines: 2027 and 2028
The Ministry gave industry and state regulators a phased runway. The dates below are the effective dates for the expanded categories; the original top-300-brand rule has been in force since 2023 under Rule 96(7).
| Drug category | Effective date | Status |
|---|---|---|
| Vaccines | 1 July 2027 | Upcoming |
| Narcotic & psychotropic drugs (NDPS) | 1 July 2027 | Upcoming |
| Anti-cancer medicines | 1 July 2027 | Upcoming |
| Antimicrobials | 1 July 2028 | Later phase |
| Top 300 brands (original mandate) | Since 2023 | In force |
Most compliant brands are choosing a dynamic QR code that points to a webpage, because excipient and other details can change without reprinting the pack. This is the lowest-friction way to stay current with the 2026 requirements.
Batch-Level vs Unit-Level: India vs DSCSA and EU FMD
A common point of confusion is the difference between India's batch-level requirement and the unit-level serialisation demanded by the US DSCSA and the EU Falsified Medicines Directive. India does not currently mandate a unique serial number on every saleable pack; it requires batch-level QR or barcode data. If you also sell into the US or EU, you typically need both: batch-level QR for Schedule H2 at home, and unit-level serialisation with aggregation and event reporting for export markets.
| Framework | Level | Key requirement |
|---|---|---|
| India — Schedule H2 | Batch-level | Nine data elements on pack; no per-pack serial |
| US — DSCSA | Unit-level | Unique serial per pack, aggregation, event reporting |
| EU — FMD | Unit-level | Unique identifier + national repository verification |
For the export side of this story, see our Pharma Serialization Compliance Update: DSCSA & EU FMD 2026 and the EU FMD 2026 / DSCSA enforcement update.
A Real 2026 Case: Why Authentication Matters
Counterfeiting in India is not theoretical. In 2026, a brand-protection associate at Glenmark alerted drug-control officials that counterfeit strips of Telma-AM, a widely prescribed blood-pressure medicine, were circulating in Gurugram. A joint Food and Drugs Administration raid seized 178 strips — 2,670 tablets — and traced the supply chain across four states to a manufacturing facility in Uttarakhand. Glenmark confirmed in writing that the seized batches were counterfeit and carried forged packaging. The case, reported by The Indian Express and ET Pharma, shows exactly the failure mode Schedule H2 targets: a genuine-looking pack that a patient cannot distinguish from the real product.
What authentication changes
A scannable, brand-controlled QR code lets a chemist, a distributor, or a patient verify the pack against the manufacturer's own record in seconds. When the code resolves to data the brand actually issued, a forged pack fails the check instead of reaching a patient.
How QR Authentication Closes the Gap for Indian Brands
A compliant Schedule H2 implementation does more than satisfy CDSCO. A well-designed QR program becomes a brand-protection and trust asset:
- Batch-encoded QR carrying all nine elements, print-ready for primary or secondary packaging.
- Dynamic QR that points to a verification page, so excipient and status details stay current without reprinting.
- Consumer verification through a simple scan, building confidence at the pharmacy counter.
- Brand-protection monitoring that flags suspected fakes when scans or reports diverge from issued data.
- Export readiness — the same platform can extend to unit-level serialisation for DSCSA and EU FMD markets.
Our related guides cover the building blocks: how unique serialization stops fakes, dynamic vs static QR codes, and QR print specs that survive the supply chain.
Implementation Checklist for Indian Pharma Brands
- Map your SKUs. Identify which formulations fall under the expanded Schedule H2 categories.
- Choose the code type. Batch-encoded QR for simplicity, dynamic QR for flexible data.
- Encode the nine elements. Confirm all mandated fields resolve on scan.
- Align artwork and line. Update primary/secondary labels and packaging artwork.
- Enable verification. Open a consumer scan page and a brand-protection monitor.
- Plan for export. If you ship to the US or EU, add unit-level serialisation on the same platform.
Frequently Asked Questions
Does Schedule H2 require unit-level serialisation?
No. India's Schedule H2 is a batch-level requirement: a QR or barcode on the pack carrying the nine data elements. It does not mandate a unique serial number on every individual saleable pack, unlike the US DSCSA or EU FMD.
Which drugs are covered by the 2026 amendment?
All vaccines, antimicrobials, anti-cancer medicines, and narcotic and psychotropic drugs under the NDPS Act, 1985, in addition to the original top 300 brands.
When do the new rules take effect?
1 July 2027 for vaccines, narcotic/psychotropic, and anti-cancer medicines; 1 July 2028 for antimicrobials. The top-300-brand rule has applied since 2023.
Who enforces Schedule H2?
CDSCO issues guidance; State Licensing Authorities handle day-to-day enforcement under the Drugs Rules, 1945, using existing inspection and penalty powers.
Can the same QR system serve export markets?
Yes. A batch-level Schedule H2 code handles the domestic mandate, and the same platform can be extended to unit-level serialisation for DSCSA and EU FMD export compliance.
About QS DEFENDER
QS DEFENDER designs QR-code, NFC, and holographic anti-counterfeit labels and traceability platforms for brands in India, the United States, and beyond. Our batch-encoded and dynamic QR solutions help manufacturers meet Schedule H2, DSCSA, and EU FMD requirements from a single system.
This article is a plain-language summary for information purposes and is not legal advice. Always confirm current obligations against the official Drugs Rules, 1945, CDSCO guidance, and the relevant Gazette notifications (including G.S.R. 506(E)). Rules and deadlines may be updated; verify with the latest official text before making compliance decisions.